The changing landscape of phase I trials in oncology.

The changing landscape of phase I trials in oncology.

Item
http://www.wikidata.org/entity/Q38629203
Evolving Concepts in Phases I and II Drug Development for Crohn's Disease.Extracellular vesicles for personalized therapy decision support in advanced metastatic cancers and its potential impact for prostate cancer.A phase 1b dose expansion study of the pan-class I PI3K inhibitor buparlisib (BKM120) plus carboplatin and paclitaxel in PTEN deficient tumors and with dose intensified carboplatin and paclitaxel.Analyses of selected safety endpoints in phase 1 and late-phase clinical trials of anti-PD-1 and PD-L1 inhibitors: prediction of immune-related toxicities.Synergistic and targeted therapy with a procaspase-3 activator and temozolomide extends survival in glioma rodent models and is feasible for the treatment of canine malignant glioma patients.Systematic comparison of the statistical operating characteristics of various Phase I oncology designs.Design considerations for early-phase clinical trials of immune-oncology agents
P2860

The changing landscape of phase I trials in oncology.

Item
http://www.wikidata.org/entity/Q38629203
description
2015 nî lūn-bûn
@nan
2015年の論文
@ja
2015年論文
@yue
2015年論文
@zh-hant
2015年論文
@zh-hk
2015年論文
@zh-mo
2015年論文
@zh-tw
2015年论文
@wuu
2015年论文
@zh
2015年论文
@zh-cn
name
The changing landscape of phase I trials in oncology.
@en
type
label
The changing landscape of phase I trials in oncology.
@en
prefLabel
The changing landscape of phase I trials in oncology.
@en
P1433
P1476
P2093
P2860
P2888
P304
P31
P356
P407
P433
P478
P577
P6179
P698
P921
P356
P1433
P1476
The changing landscape of phase I trials in oncology.
@en
P2093
P2860
P2888
P304
P31
P356
10.1038/NRCLINONC.2015.194
P407
P433
P478
P577
P6179
P698
P921